BME Group announces that it has divested twelve excess real estate assets of its Swiss Operating Company ‘BMS’ (Building Materials Suisse) to five buyers, consisting of HIAG, Swissroc Industrial Opportunities, Orllati Real Estate, IBOR and Weibel. The divestment will further enable BMS to deliver on its strategic roadmap while maximizing efficiency throughout its organization.
As part of the ongoing review of its footprint and real estate portfolio, BMS identified 12 properties with redevelopment potential, which are no longer required for its operation or required in a different configuration. Of the twelve divested assets, BMS has entered into long term lease agreements for five of the assets with two of the buyers (HIAG and Swissroc). Both buyers will invest significantly in selected sites, allowing BMS to optimize its footprint and further improve its service offering to customers.
Total gross proceeds of the divestments are CHF 94.5 million and the agreements were signed before end of March 2021. Advisors to BMS are CBRE (Real Estate), Lenz & Staehelin (Legal) and Ernst & Young (Tax).
BME Group acquires Bouwpunt Van der Gucht to strengthen its footprint in building materials in Flanders
BME Group (BME) and the shareholders of Bouwpunt Van der Gucht have reached an agreement on the sale to BME. Van der Gucht is a distributor of building materials located […]
On 11 November 2022, BME Group (BME) and Van Engeland have reached an agreement on the sale of their ironmongery activities to BME. With the acquisition, BME will densify its […]
BME Group entered exclusive negotiations with BVP-Socca to further strengthen its Infrastructure activities in the North of France
BME Group (BME) and the shareholders of BVP-Socca announce that they have entered exclusive negotiations to acquire the shares of BVP-Socca. Simultaneously, BVP-Socca announces having entered into exclusive negotiations to […]
On 1 September 2022, BME Group closed the acquisition of the activities of GBI Jacob Bakker BV, an ironmongery merchant in the east of the Netherlands. BME is one of […]
Financial results H1 2022 versus H1 2021• Revenue increased by 30.4% to reach €2,675 million• Normalized EBITDA increased by 33.6% to €225 million• Normalized EBITDA margin increased from 8.2% to […]